Supplementary Materials

Supplementary Material for:

Prostate cancer cell–stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

Xinhai Wan, Paul G. Corn, Jun Yang, Nallasivam Palanisamy, Michael W. Starbuck, Eleni Efstathiou, Elsa M. Li Ning Tapia, Amado J. Zurita, Ana Aparicio, Murali K. Ravoori, Elba S. Vazquez, Dan R. Robinson, Yi-Mi Wu, Xuhong Cao, Matthew K. Iyer, Wallace McKeehan, Vikas Kundra, Fen Wang, Patricia Troncoso, Arul M. Chinnaiyan, Christopher J. Logothetis, Nora M. Navone*

*Corresponding author. E-mail: nnavone@mdanderson.org

Published 3 September 2014, Sci. Transl. Med. 6, 252ra122 (2014)
DOI: 10.1126/scitranslmed.3009332

This PDF file includes:

  • Materials and methods: FGFR expression and copy number analysis.
  • Fig. S1. FGFR gene family expression in PDXs and the effect of dovitinib on MDA PCa 118b cells in vitro.
  • Fig. S2. Effect of 3 weeks of dovitinib treatment on mice bearing MDA PCa 118b cells in the right femurs.
  • Fig. S3. Effects of 1 and 2 days of dovitinib treatment on MDA PCa 118b bone tumors.
  • Fig. S4. Effects of 7 days of dovitinib treatment on the expression of FGFR1, p-FRS2α, p-AKT, and p-MAPK in MDA PCa 118b bone tumors.
  • Fig. S5. Expression of Fgfr2-IIIc and Fgf2 RNA, FGFR4 and FGF9RNA, and p-MAPK and eIF4E protein in mouse femurs with or without MDA PCa 118b.
  • Fig. S6. Expression of FGFR1 in PCa cells and in tumor-associated osteoblasts in bone biopsy specimens obtained from men in the dovitinib trial before treatment.
  • Table S1. Primer sequences used for RT-PCR.
  • Table S2. Quantitative RT-PCR results.
  • Table S3. Relative mRNA levels of FGF family members in bone with and without tumors.
  • Table S4. Relative mouse Fgfr1-IIIc mRNA levels in tumor-bearing bone and contralateral bone.
  • Table S5. Relative mRNA levels of FGFR1-IIIb and FGFR1-IIIc in tumorbearing bone.
  • Table S6. Expression of FGFR1 in prostate and PCa tissues, xenografts, and cell lines.
  • Legend for table S7
  • Table S8. Relative mRNA levels in tumor-bearing bone and contralateral bone in mice treated with vehicle or dovitinib.
  • Table S9. Growth plate and growth plate–to–tumor distance in MDA PCa 118b tumor–bearing bone.
  • Table S10. Serum FGF23 levels in MDA PCa 118b tumor–bearing mice treated with vehicle or dovitinib.
  • Table S11. Band intensities on Western blots of mice femurs.
  • Table S12. Bone histomorphometric analysis of contralateral (nontumorous) femurs of mice with MDA PCa 118b bone tumors.
  • Table S13. Micro-CT analysis of femurs of mice treated with vehicle or dovitinib for 4 weeks.
  • Table S14. Tumor volume of MDA PCa 118b tumor–bearing mice assessed by MRI.
  • Table S15. MDA PCa 118b tumor–bearing mice assessed by DCE-MRI after 7 days of dovitinib.
  • Table S16. Tumor volumes in mice assessed by T2-weighted fast spin-echo MRI after 3 weeks of dovitinib.
  • Table S17. Characteristics of 34 men enrolled in the dovitinib clinical trial.
  • Table S18. Toxicity events among 34 men enrolled in the dovitinib clinical trial.
  • Table S19. Findings from immunohistochemical analyses of bone biopsies obtained from men in the dovitinib trial at baseline and after 8 weeks of treatment.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S7. Copy number alterations in MDA PCa 118b cells (provided as a separate Excel file).

[Download Table S7]